TransMedics Group’s (TMDX) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of TransMedics Group (NASDAQ:TMDX) in a research note issued to investors on Tuesday morning,Benzinga reports.

Several other research firms have also recently weighed in on TMDX. Canaccord Genuity Group restated a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday, March 11th. Oppenheimer boosted their price objective on shares of TransMedics Group from $125.00 to $130.00 and gave the company an “outperform” rating in a research report on Friday, May 9th. Finally, Piper Sandler restated an “overweight” rating and issued a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $127.33.

TransMedics Group Stock Down 9.0%

TMDX opened at $124.00 on Tuesday. The company has a 50 day moving average of $113.37 and a 200 day moving average of $83.69. The company has a market cap of $4.19 billion, a PE ratio of 91.18 and a beta of 2.10. TransMedics Group has a 12 month low of $55.00 and a 12 month high of $177.37. The company has a current ratio of 9.10, a quick ratio of 8.32 and a debt-to-equity ratio of 1.92.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.29 by $0.41. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The company had revenue of $143.54 million during the quarter, compared to the consensus estimate of $123.39 million. During the same period last year, the firm earned $0.35 EPS. TransMedics Group’s revenue for the quarter was up 48.2% on a year-over-year basis. On average, sell-side analysts expect that TransMedics Group will post 1 EPS for the current year.

Insider Buying and Selling

In related news, Director Edward M. Basile sold 6,000 shares of the business’s stock in a transaction dated Friday, May 9th. The shares were sold at an average price of $115.63, for a total transaction of $693,780.00. Following the sale, the director now owns 732 shares of the company’s stock, valued at $84,641.16. The trade was a 89.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David Weill sold 732 shares of TransMedics Group stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $123.88, for a total transaction of $90,680.16. Following the completion of the transaction, the director now directly owns 12,134 shares of the company’s stock, valued at $1,503,159.92. This trade represents a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,418 shares of company stock valued at $1,512,613 over the last quarter. Corporate insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in TMDX. NBC Securities Inc. purchased a new position in shares of TransMedics Group during the first quarter valued at approximately $25,000. Smartleaf Asset Management LLC boosted its position in shares of TransMedics Group by 44.3% during the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock worth $30,000 after acquiring an additional 135 shares during the last quarter. Atlas Capital Advisors Inc. bought a new position in shares of TransMedics Group during the fourth quarter worth $31,000. Quarry LP boosted its position in shares of TransMedics Group by 88.5% during the first quarter. Quarry LP now owns 592 shares of the company’s stock worth $40,000 after acquiring an additional 278 shares during the last quarter. Finally, Hager Investment Management Services LLC boosted its position in shares of TransMedics Group by 38.3% during the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company’s stock worth $50,000 after acquiring an additional 205 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.